Abstract: This study was accompanied due to high mortality and morbidity in these patients trying to find more useful treatment. A total 54 patient with ICH Next to stroke referred to Ahwaz Golestan hospital from Jul 2008 to 2009 were selected. Patients were randomly assigned to receive a single intravenous dose of 40 μg kg -1 of rFVIIa or placebo. The performance by a clinical neurologist and based on the international ranking (Rankin's scale) on the first day of hospitalization and 90 days after discharge was evaluated. There was no significant difference in mean arterial blood pressure between placebo and patient groups. Percentage increase in both the second day of bleeding volume in the patient and placebo groups was 2.35 and 0.35%, respectively. The total difference between the first day and third day in the patient and placebo group was -7.76- and -2.99%, respectively. Patients with MAP value of more than 120 mmHg, showed a significant response to rFVIIa treatment. Recombinant activated factor VII has the potential to limit or even halt the progression of bleeding in brain hemorrhagic patients that would otherwise place growing pressure on the brain. As such, these data suggest that the use of rFVIIa holds promise in the setting of non-surgical intracranial bleeding. Whether this usage will have a positive impact on the neurological outcome lies in a future prospective clinical trial whose planning is underway.